Vivimed Labs Ltd

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Vivimed Labs Ltd witnessed a sharp decline on 5 Feb 2026, hitting its lower circuit limit of 5%, closing at ₹7.58. The stock faced intense selling pressure, marking its fourth consecutive day of losses and underperforming both its sector and the broader market indices.

Vivimed Labs Ltd witnessed intense selling pressure on 4 Feb 2026, hitting its lower circuit limit of ₹7.97, marking a maximum daily loss of 4.89%. The stock’s sharp decline reflects mounting investor concerns amid sustained negative momentum and dwindling participation.

Vivimed Labs Ltd witnessed a sharp decline on 3 Feb 2026, hitting its lower circuit limit as intense selling pressure gripped the stock. The share price plunged by 4.99% to close at ₹8.38, marking a maximum daily loss and signalling panic selling among investors amid subdued market sentiment.

Vivimed Labs Ltd witnessed a robust rally on 1 Feb 2026, hitting its upper circuit limit of 9.28, marking a maximum daily gain of 4.98%. This surge was driven by intense buying interest, resulting in a regulatory freeze on further trading and leaving a significant portion of demand unfilled.

Vivimed Labs Ltd surged to its upper circuit limit on 30 Jan 2026, registering a maximum daily gain of 4.99% as strong buying interest propelled the stock to ₹8.84. This marks the fifth consecutive day of gains, with the stock delivering a remarkable 25.64% return over this period, significantly outperforming its sector and the broader market indices.

Vivimed Labs Ltd surged to hit its upper circuit limit on 29 Jan 2026, propelled by robust buying interest and a notable 4.98% gain in a single trading session. The micro-cap pharmaceutical stock demonstrated significant investor enthusiasm despite a broader market downturn, reflecting a compelling short-term momentum that has caught the attention of traders and analysts alike.

Vivimed Labs Ltd witnessed a surge in buying interest on 28 Jan 2026, hitting its upper circuit price limit with the stock closing at ₹8.06, marking a maximum daily gain within the permitted 5% price band. This sharp upward move occurred despite the company’s overall weak market sentiment and a recent downgrade to a Strong Sell rating by MarketsMOJO, highlighting a complex interplay of demand-supply dynamics and investor behaviour in the micro-cap pharmaceutical stock.

Vivimed Labs Ltd surged to its upper circuit limit on 27 Jan 2026, registering a maximum daily gain of 4.78% as robust buying interest propelled the stock to ₹7.67. The micro-cap pharmaceutical company witnessed intense demand, triggering a regulatory freeze on further purchases and leaving a significant portion of buy orders unfilled.

Vivimed Labs. is rated Strong Sell by MarketsMOJO. This rating was last updated on 22 December 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 26 January 2026, providing investors with the latest comprehensive analysis.

Vivimed Labs has reached a new 52-week low, reflecting a sustained downward trend in its share price that has persisted over the past several weeks. The stock’s latest low price marks a significant milestone in its recent performance, underscoring ongoing concerns about the company’s financial health and market standing.

Vivimed Labs Ltd witnessed a sharp decline on 22 Jan 2026, hitting its lower circuit limit as intense selling pressure gripped the stock. The micro-cap pharmaceutical company’s shares plunged to a new 52-week low of ₹7.02, marking a significant daily loss amid widespread panic selling and unfilled supply in the market.

Vivimed Labs Ltd witnessed intense selling pressure on 21 Jan 2026, hitting its lower circuit price limit of ₹7.38, marking a new 52-week low. The stock declined by 4.9% in a single session, underperforming its sector by 5.52%, as panic selling and unfilled supply overwhelmed demand, continuing a prolonged downtrend that has seen the share price fall by over 69% in the last 20 trading days.

Vivimed Labs Ltd witnessed intense selling pressure on 20 Jan 2026, hitting its lower circuit limit and marking a new 52-week low at ₹7.76. The stock’s prolonged decline, coupled with a sharp drop in investor participation, underscores mounting concerns among shareholders amid deteriorating fundamentals and market sentiment.

Vivimed Labs has reached a new 52-week low, reflecting a sustained downward trend in its share price amid ongoing financial pressures and subdued market performance.

Vivimed Labs Ltd witnessed intense selling pressure on 19 Jan 2026, hitting its lower circuit price limit at ₹8.16, marking a fresh 52-week low and extending its losing streak to 18 consecutive sessions with a cumulative decline of 66.01%. The stock underperformed both its sector and the broader market, reflecting deep investor concerns amid dwindling participation and persistent bearish sentiment.

Vivimed Labs. is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 January 2026, providing investors with the latest insights into the company’s performance and outlook.